Client Result
Rivian IPO Underwriters Secure Appellate Victory in Securities Class Action
1 minute read | April.25.2025

1 minute read | April.25.2025
1 minute read | April.15.2025
1 minute read | May.02.2023
June.27.2022
The primary focus of the acquisition is on the lead medicine, Tazverik® (tazemetostat), a first-in-class, chemotherapy-free EZH2a inhibitor.
September.29.2021